DiaMedica Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Minnesota, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
301 Carlson Pkwy Ste 210, Hopkins, Minne...Phone Number
(763) 496-5454Website
www.diamedica.comRevenue
$22.4 MillionStock Symbol
DMACIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedicas lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.Explore more
DiaMedica Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DiaMedica Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at DiaMedica Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once DiaMedica Therapeutics has new funding data
Product Launch: Get notified when DiaMedica Therapeutics launches new products
Check out if DiaMedica Therapeutics is spiking on competitors!
DiaMedica Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if DiaMedica Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if DiaMedica Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on DiaMedica Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined DiaMedica Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to DiaMedica Therapeutics
Compare insights from companies similar to DiaMedica Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DiaMedica Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DiaMedica Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DiaMedica Therapeutics.
DiaMedica Therapeutics financials insights
Gather financial insights about DiaMedica Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$5.5M
2025
Stock/Share Issuance
$30.1M
Stock/Share Issuance
$30.1M
DiaMedica Therapeutics Tech Stack
A closer look at the technologies used by DiaMedica Therapeutics
Most Recent Scoops
Project
DiaMedica Therapeutics has observed the most clinically meaningful pharmacodynamic effects from the Part 1a IST in the mid-dose range cohorts (cohorts 4 through 8), where participants showed clinically meaningful reductions in both maternal blood pressure and the uterine artery pulsatility index. Reductions in the pulsatility index are consistent with reduced uteroplacental vascular resistance, suggesting improved blood flow to the fetus and potential modification of the underlying disease process in preeclampsia and fetal growth restriction patients.
Medical Research, Pharmaceuticals, Clinical Operations
Project
anticipates dosing the first patients shortly in both the IST early onset preeclampsia and continuous IV infusion preeclampsia studies, following a protocol amendment filed in July to adjust the dosing regimen to provide more flexibility at the mid-to-lower dose range based on results from the recently completed late-onset preeclampsia study. Dosing is expected to commence shortly after acceptance of the protocol amendment is finalized in the coming weeks.
Medical Research, Clinical Operations
Project
DiaMedica Therapeutics has completed enrollment in the first cohort of its Phase 2 early onset fetal growth restriction study, consisting of six participants treated at the 5 microgram per kg dose level. This milestone expands the clinical use of DM199 into a second serious women's health disorder for which no approved therapies currently exist.
Medical Research, Clinical Operations
Hiring Plans
DiaMedica Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
DiaMedica Therapeutics News & Media
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call March 31, 2026 8:00 AM EDTCompany ParticipantsDietrich Pauls - President, CEO & DirectorJulie...DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer - Stock Titan
Former PureTech CMO Julie Krop joins DiaMedica as it advances DM199 for preeclampsia treatment. Learn how her expertise could accelerate development. See details.DiaMedica Therapeutics Secures $30.1 Million in Private Placement - TipRanks.com
Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. DiaMedica Therapeutics has successfully closed a $30.1 million private placement of common shares, en...DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry ...
MINNEAPOLIS, July 21, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DiaMedica Therapeutics
Sign Up For FreeTo access detailed company insights
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedicas lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treat... Read More
